Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shugan Jieyu San
- Development stage
- Preclinical
- Lead developer
- Chengdu Kanghong Biotechnology
- Administration
- Oral
01
Overview
Shugan Jieyu San is a self-formulated Traditional Chinese Medicine (TCM) herbal formula. It is being investigated for its therapeutic effects in improving liver function and alleviating depression in patients with triple-negative breast cancer (TNBC). Its mechanism of action is thought to involve modulation of dopamine and serotonin pathways.
- Other names
- Shugan Jieyu San
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on Shugan Jieyu San.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shugan Jieyu San.